newsletter n°2-april. 2005oms.apvv.sk/docs/smes/iserael_2005-brokerage.pdf · 9.30-11.15:...

Newsletter n°2-April. 2005 Why you have to participate in our Natibs Exchange Fair in Tel Aviv ? ………………..…..P.2

What is our Natibs Exchange Fair?.........................................................................................P.3 Agenda…………………………………………………………………..………………………………P.4 How you can participate in?.....................................................................................................P.5 Contact us………………………………………………………………………………….……… …P.6 Who are the registered participants? (29/04/2005)…………………...…………………..P.7 to 17

t 1

www.natibs.ne

Newsletter n°2-April. 2005

SMEs, Academics and big corporations

You seek EU financing ? You need partners?

Meeting between the actors of biotechnologies and to build up

partnerships and consortia for the last call LSH 2005.

Cancer - Cell & Gene Therapy - New Molecular Diagnostics

FOCUS ON SMEs The last call of the European Commission in the field of biotechnologies and medical technologies will be largely dedicated to SMEs (approx. 30 % of the financing). SMEs of which would like to profit from this leverage to increase their activity should not miss this opportunity. Therefore, the benefits for the SMEs are:

to develop their comprehension of the instruments of the European Commission

to identify invitation of tenders or existing projects corresponding to their needs

to connect the search for partners and the assembly of a consortium

to profit from the expert opinion of the scientific committee NATIBS and its experts

to increase their chances of success with a NATIBS certification “label”

Laboratories of research can also benefit from this expert opinion.

t 2

www.natibs.ne


The NATIBS Exchange Fair takes place in the In Tel-Aviv in parallel of : The Israel BioMedical Technologies, Bio-Tech Israel 2005, Conference and Exhibition. David Intercontinental Hotel Tel Aviv, May 24-26, 2005 More information: www.kenes.com/biotech

The Natibs Exchange Fair aims at supporting :

the match making between

numerous SMEs, academics and industrials

to launch innovating project proposals to

the 4th and last call of the FP6

in the priority 1:

Life Sciences, Genomics and Biotechnology for

Health (LSH)

www.natibs.net 3


AGENDA

Wednesday (25 May 2005)

1st thematic: Cell and Gene Therapy 9.00-9.15: NATIBS Presentation 9.15-9.30: Introduction to the 4th call (focus on the thematic) Moderator: Ketty Schwarz 9.30-11.15: Presentation: 5 to 7 mins per participant 11.15-13.15: Discussion and Match Making

2nd thematic: Cancer

14.00-14.15: Introduction to the 4th call (focus on the thematic) Moderator: Ms. Montserrat Vendrell Scientif Area - Director 14.15-16.00: Presentation: 5 to 7 mins per participant 16.00-18.00: Discussion and Match Making

Thursday (26 May 2005)

3rd thematic: New Diagnostics 9.00-9.15: Introduction to the 4th call (focus on the thematic) Moderator: 9.15-11.00: Presentation: 5 to 7 mins per participant 11.00-13.00: Discussion and Match Making

4

t

www.natibs.ne

t


Do not miss this event!

You have a Natibs partner in your country?

(France, Germany, Spain, Estonia, Israel and Sweden)

Please check the list above

You do not have a Natibs partner in your country?

Please contact the Natibs coordinator or the Natibs partner in Israel: RadBioMed

5
www.natibs.ne

Coordinator

Admin. Coordinator

Mr.Jérôme Billé Chambre de Commerce et d'Industrie de l’Essonne And Strategy and Technology Research Unit – Ecole Centrale ParisFrance Ms. Astrid Costo Email: [email protected] Phone 1: +33 1 60 79 91 47 or 90 30 Web Site: www.essonne.cci.fr Mr.Philippe Deléarde Mr.Laurent Soulier Mr.Fabien Martel Organisation: Inno France [email protected] [email protected] [email protected] Phone: +33 4 92 38 84 12 WebSite: www.inno-group.de Mr.Volker Erb BioTOP Germany Email: [email protected] Phone: +49 30 31 86 22 15 Web Site: www.biotop.de Mr.Ingemar Ahlandsberg Novum Research Park Sweden Email: [email protected] Phone: +46 87 46 00 84 Web Site: www.novum.se Mr.Gabriel Mergui Genopole Evry France Email: [email protected] Phone: +33 1 60 87 83 05 Web Site: www.genopole.org Mr.Kaupo Pastak Tehnopol Estonia Email: [email protected] Phone: +372 6 800 200 Web Site: www.tehnopol.ee Mr IdanTamir RAD BioMed Israel Email: [email protected] Phone: +972 3 5312604 Web Site: www.radbiomed.com Mr. Andreas Mätzold BBB Management Campus Berlin-Buch Germany Email: [email protected] Phone: +49 30 94 89 26 96 Web Site: www.bbb-berlin.de Ms. Montserrat Vendrell Parc Cientific de Barcelona Spain Email: [email protected]


7t

www.natibs.ne

*Advancell (Company – Spain)

Seeking for:

• Distributors for CacoReady™ (ready-to-use Caco-2 cells) • Agents for our services of cell research "a la carte" • Partners for pharmaceutical development using nanotechnology for peptide and DNA delivery

Contact person: Lluis Ruiz www.advancell.net

*Combinatorial Chemistry for Medicinal Targets (Academic – Spain) Barcelona Science Park-University of Barcelona Combinatorial and HTOS techniques are used for drug discovery in several important medicinal targets, such as GPCR, cancer, and metabolism disfunction. Furthermore, peptide based vaccines are developed for different types of cancer. New drug delivery systems are being also developed based in peptide dendrimers and foldamers.

Contact: Dr. Fernando Albericio Professor of Organic Chemistry at the University of Barcelona Group Leader at the Barcelona Biomedical Research Institute Barcelona Science Park Josep Samitier 1 08028-Barcelona Spain phone: 34 93 403 70 88 fax: 34 93 403 71 26 email: [email protected]

*Oryzon Genomics (Company-Spain)

ORYZON Genomics, has created a list of tools in the fields of: - Genomics, Proteomics, Bioinformatics

Their applications are focused in two main market areas:

- Agro market: development of new crop varieties - Molecular Diagnostics: development of new molecular diagnostics kits and disease prognosys


t 8

www.natibs.ne

Contact persons. Tamara Maes, Josep Mª Echarri www.oryzon.com

*Vall d’Hebron Research Hospital (Academic-Spain)

Dr. Reventos is a highly respected scientist in the field of cancer, in particular his group is interested inprostate and endometrial cancer. Mr Jaume Reventos www.vhebron.es

*Invitek Gesellschaft für Biodesign und Biotechnologie mbH (Company-Germany)

Development of molecular platform-technologies for nucleic acid extraction and analysis. Development of specific gene tests for biomedical research and molecular pathway analysis. Development of recombinant antigens for drug discovery and clinical diagnostics.

Topic(s) of interest: Development of new diagnostics (STREP dedicated to SME´s )

Contact: www.invitek.de

*Glycotope GmbH (Company – Germany) GlycoEngineering is the technology to generate new expression cell lines with defined glycosylations. GlycoExpress™ is the novel biotechnologically suitable expression platform which allows the generation of proteins with fully human glycosylation, higher activity, optimized pharmacokinetics or reduced dosing. This technology is ideal for a critical improvement of a pharmaceutical protein product or for the development of a more effective new generation of generic blockbusters with a new patent protection. Biomolecules, their glycosylation, and the glycosylation machinery of a production cell line can be structurally analysed by the whole range of glycoanalytical methods using the GlycoAnalytics and GlycoProfiling technologies.

Topics of interest: “Development of new in vitro tests to replace animal experimentation” including the integrated project “Predictive in vitro testing for human exposure to chemicals" or the STREP with a similar topic.

Contact: www.glycotope.com

*Research Institute for Molecular Pharmacology (Academic – Germany) Prof. Rademann, Group Medicinal Chemistry -Chemical biology with small molecules

Treatment concepts currently available for cardiac and circulatory diseases, cancer, diseases of the central nervous system and immune system, certain infectious diseases, and numerous rare diseases are frequently unsatisfactory. This is essentially attributable to the still very often inadequate knowledge of the molecular basis of biological regulation processes and thus of the molecular basis of diseases, despite considerable progress made in recent years. The aim of the FMP is to help eliminate this fundamental deficiency by elucidating regulation processes at the molecular level, and based on this, to develop new causal approaches to pharmacological interventions.

Newsletter n°2-April. 2005 w

*HealthTwist GmbH (Company-Germany) Service provider in the field of human functional genetics. Based on a register of twin families with phenotypic and genotypic information for selection, HealthTwiSt is organizing medical genetics studies in twins and sib pairs to deliver complete sets of clinical data, biological samples, and genotypes or DNA, as well as bioinformatics know-how and statistical genetics. The approach of functional genetics of quantitative traits in a highly informative sample is bridging the gap between animal/cell based studies and application in man, saving time and financial resources. Conventional target validation is extended by quantitative target ranking.

Testing in the fields of nutriceuticals / functional food / wellness products based on on the co-twin approach

Topics of interest: Transfer of functional genomics results from animal models to man

Advanced genomics and its application for health

*Max Delbrück Center for Molecular Medicine Berlin-Buch (Academic-Germany) Three extensive research programs define the profile of the MDC: Cardiovascular and Metabolic Diseases Cancer Research, Function and Dysfunction of the Nervous System Topics of interest: Stem cell therapy for stroke patients" (LSH-2005-1.2.4.-3) (in research partnership with epo) *Epo experimentelle pharmakologie & onkologie berlin-buch GmbH (Company-Germany) Preclinical pharmacological testing of novel therapeutics and diagnostics. Developement of new antineoplastic agents (cytostatics, biologicals, immunomodulators, gene therapeutics). Broad panel of murine and human tumors growing in immunocompetent (SPF-quality, sygeneic strains) or immunodeficient (nude , SCID, NOD/SCID) mice. Development of tailor-made testing procedures.

Techniques and Methods: Xenogeneic tumour models (Nude-, SCID-, NOD/SCID-mice) Syngeneic tumour models; PCR, RT-PCR (e.g. resistance markers,estrogen receptor, cytokine genes); In vitro cytotoxicity (MTT-Test) Immunohistochemistry (e.g. apoptosis markers, signal transduction molecules) ; Colony forming assay (stem cell determination in bone marrow); FACS (analysis of different cell types); ELISA-tests (e.g. determination of cytokines); Side effects of treatment modalities (lethality, body weight, blood chemistry, blood cells, bone marrow differentiation);Pharmacokinetics

Topic of interest: Stem cell therapy for stroke patients" (LSH-2005-1.2.4.-3) partnership

(In research partnership with MDC as well as an University in Warsaw )

ww.natibs.net 9

Newsletter n°2-April. 2005 t
10 www.natibs.ne
*CureTech (Company-Israel) CureTech is developing breakthrough monoclonal antibody-based therapeutics and vaccines for the treatment of cancer

and other immune related diseases. Utilizing certain features of the immune system the company's technology leads to

immune modulation, thus providing a broad platform for product development in a variety of therapeutic areas.

*TK-Signal (Company-Israel)

TK-Signal is developing a series of radioactive small molecules that will act as medical nuclear imaging tracers for the

detection and diagnosis of cancer cells. The compounds are based upon their specific binding capabilities to EGFR-TK

(Epidermal Growth Factor Receptor - Tyrosine kinase).

*BioGal (Company-Israel)

BioGAL is a market-driven developer of drug applications for cancer. The Company has patented (PCT, pending) the

use of Erythropoietin (Epo) against Multiple Myeloma(MM), an incurable hematological cancer of plasma cells. Clinical

observations in human patients and research in animals have shown that Epo could be highly effective in MM. BioGAL

is also examining the effect of Epo on additional potential cancer types.

*CAN-Fite (Company-Israel) Can-Fite Biopharma is a biopharmaceutical company that focuses on the research and development of proprietary

drugs for use in cancer treatment. The company is developing AFite and RedTox for use in cancer therapy, as well as

NeutraMF, a nutritional supplement for use in the prevention of cancer. Can-Fite's drug development program stems

from the observation that cancer does not metastasize into muscle tissue and the subsequent discovery of natural anti-

cancer small molecules secreted by the muscle cells.

*CurePeptide (Company-Israel)

Cure Peptide developed a new and unique peptide. The unique proprietary peptide of the company , is binding to the

adenocarcinoma cells, through typical receptors that are over-expressed in adenocarcinoma type cancer cells.

The peptide also destroys these cancer cells, without the need to conjugate it to chemotherapeutic substance. It holds

the promise for a very effective and safe treatment for all types of adenocarcinoma cancer.


t

11
www.natibs.ne
*D-Pharm (Company-Israel)

D-Pharm is a clinical-stage biopharmaceutical company pioneering the development of Lipid-Like

Therapeutics. D-Pharm is engaged in both drug targeting and drug discovery based on the company's

technological platforms: (i) Regulated Activation of Prodrugs (D-RAP(TM)); (ii) Membrane Activated

Chelators (MAC); and (iii) LipidoMimetix(TM). This has enabled the company to generate a pipeline of

innovative drugs for the treatment of CNS disorders, cancer, and autoimmune diseases.

*Vascular Biogenics (Company-Israel)

Vascular Biogenics (VBL) is a biopharmaceutical company dedicated to the development of innovative

therapies targeting the vascular wall. VBL's products introduce novel approaches to the fight against cancer

and cardiovascular diseases. VBL's vision is to develop safe and simple solutions based on in-depth

understanding and on mimicking of natural processes occurring within the vascular wall

*Neuro-survival technologies NST (Company-Israel) NST is a molecular imaging and drug development company, focusing on identification and

targeting of cells undergoing apoptosis (programmed cell death). NST has developed a set of

proprietary compounds with demonstrated ability to identify, bind and accumulate within

apoptotic cells in-vivo. This technology addresses a huge market of unmet clinical need

across a range of molecular imaging and therapeutic applications including cancer and heart

disease.

*Gideon Rechavi MD PhD, Professor, Head of Pediatric Hematology-Oncology at the Sheba Medical Center – (Academic-Israel)

*Prof. Tamar Perez , Director - Sharett Institute for Oncology, Hadassa Medical Center (Academic-Israel)

*Prof. Lea Eisenbach - The George F. Duckwitz Professor of Cancer Research, Weizmann Institute (Academic-Israel)

12 www.natibs.ne
*Prof. Moshe Oren – Dean, Faculty of Biology, Department of Molecular Cell Biology, Weizmann Institute (Academic-Israel)

*Prof. Aaron Cihanower – Nobel laureate (chemistry 2004), Rappaport Medical Center the Technion (Academic-Israel)

*Alberto Gabizon- Professor of Oncology, HEBREW UNIVERSITY SCHOOL OF MEDICINE and Head of Oncology Institute, SHAARE ZEDEK MEDICAL CENTER, ISRAEL. (Academic-Israel) Prof. Gabizon was a central contributor to the development of Doxil, a smart chemotherapy “drug

carrier” with tumor-targeting properties. Doxil, approved for the treatment of Kaposi 's sarcoma,

ovarian cancer, and breast cancer is being increasingly used in the treatment of various forms of

cancer.

*Hapto biotech (Company-Israel)

The company has fabricated fibrin microbeads (FMB) that can be used to isolate cells and grow them

to achieve high cell numbers. These cells can then be transplanted to wounds to regenerate tissue.

Other Hapto innovations are based on small peptides that instigate the mechanism of cell attachment

to fibrin. The haptotactic peptides can be used to target drugs for cell uptake or to coat the surfaces of

devices intended for implantation.

*MGVS (Academic-Israel) MGVS develops gene and cell therapy products to address a number of vascular-related disorders in

a variety of disease areas. MGVS aims to provide effective therapeutic alternatives in patients who

cannot undergo angioplasty or conventional bypass surgery, and may also offer additional valuable

treatment for many patients with arterial occlusive disorders.

*Prochon Biotech (Company-Israel) Prochon Biotech is an Israeli biotechnology company devoted to the discovery, development and

commercialization of novel therapeutic approaches for the treatment of genetic and acquired skeletal

disorders.These include short-limbed dwarfism, benign and malignant tumours of bone and cartilage,

inflammatory joint disorders, bone fracture healing and cartilage repair, based on its strong molecular

biology platform, proprietary growth factors and tissue engineering related technology

13 www.natibs.ne
* Proneuron Biotechnologies Inc. (Company-Israel) Proneuron Biotechnologies is in advanced stages of clinical development in a number of neurological

markets. Proneuron harnessed the power of the body's own immune system for the treatment of

debilitating central nervous system (CNS) disorders. Proneuron is determined to establish itself as a

fully integrated company that will independently develop and commercialize therapies for niche CNS

disorders. Proneuron is currently focusing its expertise in cell therapy and neuroimmunology on the

development and commercialization of a treatment for spinal cord injuries (SCI) as well as other

neurological disorders, which until now were considered incurable. *GamidaCell (Company-Israel)

Gamida-Cell is a leader in the expansion of hematopoietic (blood) stem cell therapeutics in clinical

development for cancer and autoimmune diseases, as well as future regenerative cell-based

medicines. The company is currently engaged in an IND Phase I/II study of its flagship product

StemEx(R) for the treatment of leukemia and lymphoma

*GeneGrafts (Company-Israel) GeneGrafts is developing a novel therapy for atrial fibrillation (AF). GeneGrafts is developing a

transkaryotic approach using autologous (extracted from the patient) genetically modified cells that are

delivered to the patient’s heart by catheterization. The treatment is localized and involves a single

procedure

*BetaO2 Technologies (Company-Israel) Beta-O2 develops technology to supply oxygen to transplanted cells. The first application of this technology will supply

oxygen to islet cells, which are transplanted into diabetics who require insulin for day-to-day functioning

14 www.natibs.ne
*BrainStorm Cell-Therapeutics (Company-Israel) BrainStorm Cell Therapeutics is developing neural-like stem cell therapeutic products, NurOwn(TM), based on

autologous bone marrow derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(TM) patent

pending technology is enabling the differentiation of bone marrow derived stem cells into functional neurons, as

demonstrated in animal models.

CellCure (Company-Israel) Cell Cure, jointly owned by ES Cell International (ESI) and Hadasit, is active in nerve cells and nervous disorders (such

as Parkinson), based on ESI technology. Cell Cure is a stem cell therapy company focused on cures for Parkinson’s and

other neurodegenerative diseases

*Prof. Benjamin Reubinoff (Academic-Israel) Director of Hadassah Medical Center human embryonic stem cell research center

*Prof. Tamir Ben-Hur, (Academic-Israel) the Agnes Ginges center for human neurogenesis ( stem-cells), Hadassah Medical Center

*Moshe Flugelman MD, (Academic-Israel) Prof. of gene therapy in vascular biology and atherosclerosis, Rappaport Medical Center, the

Technion

*Dr. Lior Gepstein (Academic-Israel) expert on growing precursors of heart cells from embryonic stems cells, Rappaport Medical center, the

Technion

*Jonathan Leor MD, (Academic-Israel) Prof. of cardiology. Director of Neufeld Cardiac Research Institute, Sheba Medical Center ( cell

therapy, gene therapy)

15 www.natibs.ne
*Prof. Yoseph Itzkowitz-Eldor, (Academic-Israel) Head – Rambam Hospital Gynecology Department, partner to the patent for creating embryonic stem

cells

*Prof. Dror Mevorach M.D., (Academic-Israel) The Laboratory for Cellular and Molecular Immunology, Department of Medicine, Hadassah Medical

Center

*Procognia (Company-Israel) Procognia is committed to exploiting an ever-expanding knowledge in proteins to increase the quality of biopharmaceuticals and small molecule therapeutics and thereby the quality of medical care

(automated glycoanalysis and protein function arrays).

*Glycominds (Company-Israel) Glycominds is a Specialty Tests Company, focusing on high valued tests for autoimmunity. Our initial

products are based on our newly discovered biomarkers for Multiple Sclerosis (MS) and Crohn's

Disease (CD).

*Irun Cohen (Academic-Israel) The Helen and Morris Mauerberger Professor of Immunology

*Anat Achiron (Academic-Israel)

*Gidi rehavi (Academic-Israel)

*Arye Shalev (Academic-Israel) The Psychiatry Department, Director, Hadassah medical hospital.

*Ruth Gabizon- (Academic-Israel) Neurology department, Hadassah medical school


t
16 www.natibs.ne
*Signature Diagnostics (Company-Germany)

Signature Diagnostics, a new biotechnology company based in Potsdam, is

positioned in oncogenomics / clinical oncology and dedicated to the

development of novel molecular diagnostics for predicting outcome and drug

responsein cancer patients.

Thus, Signature Diagnostics provides novel diagnostic tools for cancer

patients and healthcare providers. The company also supports and improves

the clinical development of innovative oncology drugs in collaboration with

clinical partners and pharmaceutical companies.

Signature Diagnostics strongly believes that signature-based patient

selection and stratification of patient subgroups will soon become an

important component of the clinical development process of existing and

novel oncology drugs and drug combinations. It enables the improvement of

the patient treatment efficacy, as well as reducing significantly the

development cost. Signatures approach is a significant step towards

personalized medicine in oncology.

*Mr Joeri Borstlap (Academic/Company – Germany)

Mr. Joeri Borstlap represents the network CellNet.Org and covers all

activities from scientists and companies in regenerative medicine.

CellNet.Org promotes research networking, pushes for the advancement of

clinical studies and education programs for specialists in the field,

supports economic activities and the commercialization of developments in

the area of Regenerative Medicine, and shares the knowledge gathered with

the public.

CellNet.Org aims to strengthen competitiveness by promoting networks at both

regional and international level, and to bring together American, Asian and

European initiatives. CellNet.Org fosters cooperation between universities,

research centers, enterprises, including SMEs, and science and technology

organizations.


*Ketty Schwarz (Academic-France) *David Klatzmann (Academic-France) *Odile Haguenauer (Academic-France) *Celecure Ltd (Company-Estonia) *OCRC Ltd (Company-Estonia)

17

newsletter n°2-april. 2005oms.apvv.sk/docs/smes/iserael_2005-brokerage.pdf · 9.30-11.15:...

Documents